Sign in Create account

Themis Medicare Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: THEMISMED BSE: 530199
₹116.46
▼ -3.49 (-2.91%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
66/100
Moderate
Valuation
55/100
Fairly Valued
Momentum
48/100
Neutral

QVM read Mixed signals Quality Moderate, Valuation Fairly Valued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹1,073 Cr
PE (TTM)
35.8
Industry median 36.1 (152 companies)
Price to Book
2.7
PEG (TTM)
0.1
Institutions holding %
0.02%
FII + DII, latest filed period
Piotroski Score
2
Relative return vs Nifty50, qtr %
9.9
Relative return vs Sector, qtr %
5.2
Free Cash Flow
₹-8 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
286.83%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
515.68%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-8.56%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
286.92%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-10.88%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.84
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.25
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
4.98
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
33.05%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
52.56%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
16.81%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
0.19%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
-0.33%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
0.29%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

1 of 7 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 2)
  • Yes Debt to equity is below 0.5 (0.25)
  • No Return on equity is 15% or more (0.3%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

1 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • No Promoter pledge is 5% of their holding or less and not rising (43.4% pledged)

Peer comparison

1 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

1 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Fair Value Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-2.9%
Low 115.2500 · High 122.1900
1W return
-4.5%
Low 115.2500 · High 126.0000
1M return
-6.7%
Low 115.2500 · High 140.6000
52W return
-13.0%
Low 64.9500 · High 147.0000
Lifetime High ₹1921.7000 (Oct. 3, 2023)
Lifetime Low ₹40.0000 (Sept. 4, 2013)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish2
Bearish4
5D
118.3
10D
119.8
20D
120.7
50D
117.7
100D
112.1
200D
100.5

Delivery and volume

Day avg. delivery
47.6%
Week avg. delivery
71.4%
Month avg. delivery
29.7%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

117.97
Pivot
First resistance120.68
Second resistance124.91
Third resistance127.62
First support113.74
Second support111.03
Third support106.80
Day RSI44.1
Day MFI29.1
Day MACD-0.12
Day MACD signal1.26

Beta

1M0.72
3M0.57
1Y1.33
3Y1.42

Price change analysis

↓ -6.7%
Over 1 Month
LowHigh
115.25140.60
↑ 5.2%
Over 3 Months
LowHigh
101.25140.60
↑ 57.0%
Over 6 Months
LowHigh
71.20140.60
↓ -13.0%
Over 1 Year
LowHigh
64.95147.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 35.8 (own history: 10.0–68.6)
Fair Value Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹87 Cr
Net profit (June 30, 2026)
₹29 Cr
Basic EPS (June 30, 2026)
₹3.1200

Ranks #91 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter67.11%
  • FII/FPI0.01%
  • Other DII0.01%
  • Public32.87%

Largest holders

NameCategoryShares %Shares
Dinesh Shantilal Patel, Jayshree Dinesh Patel, Sachin Dinesh Patel (Trustees of Vividhmargi Trust)Promoter27.4900%25317620
Vividhmargi Investments Private LimitedPromoter26.5200%24429460
Gedeon Richter Investment Management Ltd.Promoter9.6000%8843080
Anuj Anantrai ShethPublic3.8000%3500000
Zafar AhmadullahPublic2.1100%1945964

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 67.11% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 0.11% to 0.01% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings were unchanged at 0.00% in Jun 2026 qtr

All shareholding details →

Insider trading, SAST & pledges

All 23 insider trades, 20 SAST, 10 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
4 Jan 2023 Prakash Naringrekar Other Sell 0 ₹0
4 Jan 2023 Prakash Naringrekar Other Sell 0 ₹0
4 Jan 2023 Prakash Naringrekar Other Sell 0 ₹0
4 Jan 2023 Prakash Naringrekar Other Sell 0 ₹0
2 Jul 2021 Prakash Naringrekar Other Sell 0 ₹0
2 Jul 2021 Prakash Naringrekar Other Sell 0 ₹0
30 Jun 2021 Prakash Naringrekar Other Sell 0 ₹0
29 Jun 2021 Prakash Naringrekar Other Sell 0 ₹0
24 Jun 2021 Prakash Naringrekar Other Sell 0 ₹0
22 Jun 2021 Prakash Naringrekar Other Sell 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 18 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
9 Oct 2025 NK SECURITIES RESEARCH PRIVATE LIMITED Bulk Sell 685,949 141.7200 NSE
9 Oct 2025 NK SECURITIES RESEARCH PRIVATE LIMITED Bulk Buy 685,949 141.6100 NSE
9 Oct 2025 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 659,356 141.6300 NSE
9 Oct 2025 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 659,356 141.3200 NSE
2 Jun 2021 TEJAS TRADEFIN LLP Bulk Buy 72,009 735.7600 NSE
12 Mar 2013 GAGANDEEP CREDIT CAPITAL PRIVATE LIMITED Bulk Sell 112,500 60.2500 BSE
12 Mar 2013 ANUJ ANANTRAI SHETH Bulk Buy 112,500 60.2500 BSE
26 Mar 2010 THEMIS DISTRIBUTORS PVT. LTD. Bulk Buy 234,612 181.5000 BSE
26 Mar 2010 KISHORCHAND RATULSIDAS LAKDAWALA Bulk Sell 235,712 181.5000 BSE
4 Mar 2010 KISHOR CHANDRA TULSIDAS LAKDAWALA Bulk Sell 89,976 175.0000 BSE

All bulk and block deals →

Corporate Actions

Full history (1 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Themis Chemicals Ltd. to Themis Medicare Ltd.

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
13 Aug 2026 Financial Results Yes
28 May 2026 Financial Results/Dividend Yes
13 Feb 2026 Fund Raising —
13 Feb 2026 Financial Results Yes
13 Nov 2025 Financial Results Yes

Corporate Announcements

All 8 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
1 Oct 2026 AGM/EGM Themis Medicare Ltd - 530199 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
30 Sep 2026 AGM/EGM Themis Medicare Ltd - 530199 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
30 Sep 2026 AGM/EGM Themis Medicare Ltd - 530199 - Shareholder Meeting / Postal Ballot-Outcome of AGM
30 Sep 2026 Company Update Themis Medicare Ltd - 530199 - Announcement under Regulation 30 (LODR)-Credit Rating
30 Sep 2026 Company Update Themis Medicare Ltd - 530199 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
30 Sep 2026 Company Update Themis Medicare Ltd - 530199 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
18 Sep 2026 Corp. Action Themis Medicare Ltd - 530199 - Corporate Action -Fixed Record Date For Dividend For FY 2025-26.
9 Sep 2026 Company Update Themis Medicare Ltd - 530199 - Announcement under Regulation 30 (LODR)-Newspaper Publication

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong net profit margin (33.0%)
  • Low financial leverage (Debt/Equity 0.25)
  • Healthy liquidity (Current Ratio 1.84)

Weaknesses

  • Low Return on Equity (0.3%)
  • Declining revenue YoY (-10.9%)

Opportunities

  • PEG below 1 (0.08) -- earnings growth outpacing its own valuation

Threats

  • PE above 35 (35.8) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Themis Medicare Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.